Structured evidence table for Coq10 Cholesterol Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Coq10 Cholesterol Randomized Trial | Increasing evidence also suggests that dysregulated lipid and glucose metabolism can aggravate chronic inflammation, which in return exacerbates metabolic disorders, forming a vicious cycle. | 1 | Zhang Zhuo (2026) | Effects of Coenzyme Q10 on Lipid, Glycemic, and Inflammatory Markers in Metabolic Disorders: A Systematic Review and Meta‐Analysis |
| Coq10 Cholesterol Randomized Trial | CoQ10 exists in two interconvertible forms: ubiquinone (oxidized) and ubiquinol (reduced). | 1 | Zhang Zhuo (2026) | Effects of Coenzyme Q10 on Lipid, Glycemic, and Inflammatory Markers in Metabolic Disorders: A Systematic Review and Meta‐Analysis |
| Coq10 Cholesterol Randomized Trial | During or after intestinal absorption, ubiquinone is readily reduced to ubiquinol, which accounts for more than 95% of circulating CoQ10. | 1 | Zhang Zhuo (2026) | Effects of Coenzyme Q10 on Lipid, Glycemic, and Inflammatory Markers in Metabolic Disorders: A Systematic Review and Meta‐Analysis |
| Coq10 Cholesterol Randomized Trial | 1 2 3 4 5 7 8 9 α α Abnormal lipid and glycemic metabolism is closely linked to the occurrence and development of various metabolic diseases, including dyslipidemia, diabetes, coronary artery disease (CAD), and metabolic syndrome, and poses a significant global health burden. | 1 | Zhang Zhuo (2026) | Effects of Coenzyme Q10 on Lipid, Glycemic, and Inflammatory Markers in Metabolic Disorders: A Systematic Review and Meta‐Analysis |
| Coq10 Cholesterol Randomized Trial | 3 4 5 6 7 8 9 10 9 11 12 13 14 It is well established that aging increases the risk of developing metabolic [,], cardiovascular [,], and neurodegenerative diseases [,]. | 4 | Wiciński Michał (2026) | Review of Therapeutic Potential of Coenzyme Q10 in Ophthalmology: Focus on Age-Related Macular Degeneration, Glaucoma, and Retinitis Pigmentosa |
| Coq10 Cholesterol Randomized Trial | For numerous ocular diseases, aside from genetic factors and other comorbidities, advancing age constitutes a significant risk factor. | 4 | Wiciński Michał (2026) | Review of Therapeutic Potential of Coenzyme Q10 in Ophthalmology: Focus on Age-Related Macular Degeneration, Glaucoma, and Retinitis Pigmentosa |
| Coq10 Cholesterol Randomized Trial | This results in the development of cataracts and the decline in retinal pigment cell function associated with macular degeneration []. | 4 | Wiciński Michał (2026) | Review of Therapeutic Potential of Coenzyme Q10 in Ophthalmology: Focus on Age-Related Macular Degeneration, Glaucoma, and Retinitis Pigmentosa |
| Coq10 Cholesterol Randomized Trial | 1 2 Due to advancements in medical science and improvements in the quality of life, the global population is aging. | 4 | Wiciński Michał (2026) | Review of Therapeutic Potential of Coenzyme Q10 in Ophthalmology: Focus on Age-Related Macular Degeneration, Glaucoma, and Retinitis Pigmentosa |
Source documents